Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On August 11, 2026, in connection with Mr. Naor’s appointment (as described below), Francis X. Brown III’s appointment as Neuronetics, Inc.’s (the “Company”) interim principal financial and accounting officer ended.…
Filed Aug 17, 2026Accepted Aug 17, 2026, 4:10 PM EDTCIK 1227636Accession 0001193125-26-354051
Neuronetics, Inc. is a leader in interventional mental health, combining innovative treatment technologies with direct patient care. Through its NeuroStar® Advanced Therapy system, the Company is a leading provider of transcranial magnetic stimulation (“TMS”) treatment and, through Greenbrook TMS Inc. (“Greenbrook”), operates one of the largest interventional psychiatry clinic networks in the United States, offering both TMS and SPRAVATO® therapies. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. NeuroStar Advanced Therapy is the leading TMS treatment for major depressive disorder (“MDD”) in adults and is backed by what we believe is the largest clinical data set of any TMS treatment system for depression. Greenbrook treatment centers also offer SPRAVATO® (esketamine) nasal spray, a prescription medicine indicated for the treatment of treatment-resistant depression (“TRD”) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with MDD with acute suicidal ideation or behavior in conjunction with an oral antidepressant. 1
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) On August 11, 2026, in connection with Mr. Naor’s appointment (as described below), Francis X. Brown III’s appointment as Neuronetics, Inc.’s (the “Company”) interim principal financial and accounting officer ended. Such event is not the result of any dispute or disagreement between Mr. Brown and the Company, the Company’s management, or the Company’s Board on any matter relating to the Company’s operations, policies, or practices. Mr. Brown will continue to serve as a consultant.
(c) As previously disclosed, the Board of Directors of the Company (the “Board”) appointed Nir Naor as the Company’s Executive Vice President, Chief Financial Officer, and Treasurer with an effective date of July 23, 2026. On August 12, 2026, the Board appointed Mr. Naor to serve as the Company’s principal financial and accounting officer. Mr. Naor’s title is now Executive Vice President, Chief Financial Officer, Corporate Secretary, and Treasurer. Mr. Naor did not receive any new compensation in connection with his appointment as the principal financial and accounting officer, his appointment as the corporate secretary, or the modification of his title. Mr. Naor’s biographical information can be found in the Company’s Current Report on Form 8-K filed on July 20, 2026.
There is no arrangement or understanding between Mr. Naor and any other person pursuant to which Mr. Naor was selected as an officer of the Company, and there is no family relationship between Mr. Naor and any of the Company’s directors or other executive officers. There are no related party transactions between Mr. Naor and the Company that would require disclosure under Item 404(a) of Regulation S-K.
